Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Cerilliant
Merck
QuintilesIMS
Colorcon
Cantor Fitzgerald
Farmers Insurance
AstraZeneca
Fuji

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208411

« Back to Dashboard

NDA 208411 describes NARCAN, which is a drug marketed by Adapt and Bristol Myers Squibb and is included in five NDAs. It is available from two suppliers. There are seven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NARCAN profile page.

The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

Summary for 208411

Tradename:1
Applicant:1
Ingredient:1
Patents:7
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 208411

Mechanism of ActionOpioid Antagonists

Medical Subject Heading (MeSH) Categories for 208411

Suppliers and Packaging for NDA: 208411

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411 NDA Lake Erie Medical DBA Quality Care Products LLC 55700-457 55700-457-01 2 VIAL, SINGLE-DOSE in 1 PACKAGE (55700-457-01) > .1 mL in 1 VIAL, SINGLE-DOSE
NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411 NDA Adapt Pharma, Inc. 69547-212 69547-212-04 4 VIAL, SINGLE-DOSE in 1 PACKAGE (69547-212-04) > .1 mL in 1 VIAL, SINGLE-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength4MG/SPRAY
Approval Date:Nov 18, 2015TE:RLD:Yes
Patent:► SubscribePatent Expiration:Mar 16, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 16, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 16, 2035Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
Julphar
Merck
AstraZeneca
Argus Health
Dow
UBS
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot